Development of ketobenzothiazole-based peptidomimetic TMPRSS13 inhibitors with low nanomolar potency

5Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

TMPRSS13, a member of the Type II Transmembrane Serine Proteases (TTSP) family, is involved in cancer progression and in respiratory virus cell entry. To date, no inhibitors have been specifically developed for this protease. In this study, a chemical library of 65 ketobenzothiazole-based peptidomimetic molecules was screened against a proteolytically active form of recombinant TMPRSS13 to identify novel inhibitors. Following an initial round of screening, subsequent synthesis of additional derivatives supported by molecular modelling revealed important molecular determinants involved in TMPRSS13 inhibition. One inhibitor, N-0430, achieved low nanomolar affinity towards TMPRSS13 activity in a cellular context. Using a SARS-CoV-2 pseudovirus cell entry model, we further demonstrated the ability of N-0430 to block TMPRSS13-dependent entry of the pseudovirus. The identified peptidomimetic inhibitors and the molecular insights into their potency gained from this study will aid in the development of specific TMPRSS13 inhibitors.

Cite

CITATION STYLE

APA

Joushomme, A., Désilets, A., Champagne, W., Hassanzadeh, M., Lemieux, G., Gravel-Trudeau, A., … Leduc, R. (2025). Development of ketobenzothiazole-based peptidomimetic TMPRSS13 inhibitors with low nanomolar potency. Journal of Enzyme Inhibition and Medicinal Chemistry, 40(1). https://doi.org/10.1080/14756366.2025.2466841

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free